{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:21:02Z","timestamp":1767151262213,"version":"build-2238731810"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had\n                    <jats:italic>TP53<\/jats:italic>\n                    <jats:sub>mut\/del<\/jats:sub>\n                    CLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD \u00b0II\u2013IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse\/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted.\n                  <\/jats:p>","DOI":"10.1038\/s41409-020-01069-w","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T20:03:20Z","timestamp":1601582600000},"page":"605-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-2981","authenticated-orcid":false,"given":"Johannes","family":"Schetelig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hoek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronjon","family":"Chakraverty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Browne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Malagola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghandi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Maury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie Nguyen","family":"Quoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paneesha","family":"Shankara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Brecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5216","authenticated-orcid":false,"given":"Mathilde","family":"Hunault-Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Bittenbring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Lepretre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Baldauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesbeth C.","family":"de Wreede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2961-4183","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"1069_CR1","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","volume":"128","author":"AR Mato","year":"2016","unstructured":"Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128:2199\u2013205.","journal-title":"Blood"},{"key":"1069_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","volume":"19","author":"JA Jones","year":"2018","unstructured":"Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65\u201375.","journal-title":"Lancet Oncol"},{"key":"1069_CR3","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","volume":"131","author":"S Coutre","year":"2018","unstructured":"Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018;131:1704\u201311.","journal-title":"Blood"},{"key":"1069_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood.2018882555","volume":"134","author":"AW Roberts","year":"2019","unstructured":"Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019;134:111\u201322.","journal-title":"Blood"},{"key":"1069_CR5","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","volume":"28","author":"AR Mato","year":"2017","unstructured":"Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28:1050\u20136.","journal-title":"Ann Oncol"},{"key":"1069_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1182\/hematology.2019001321","volume":"2019","author":"JA Woyach","year":"2019","unstructured":"Woyach JA. Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. Hematol Am Soc Hematol Educ Program. 2019;2019:476\u201381.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1069_CR7","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","volume":"26","author":"AR Mato","year":"2020","unstructured":"Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res. 2020;26:3589\u201396.","journal-title":"Clin Cancer Res"},{"key":"1069_CR8","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1097\/PAS.0000000000000525","volume":"39","author":"CY Louie","year":"2015","unstructured":"Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA. Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol. 2015;39:1653\u201360.","journal-title":"Am J Surg Pathol"},{"key":"1069_CR9","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"SE Coutre","year":"2015","unstructured":"Coutre SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779\u201386.","journal-title":"Leuk Lymphoma"},{"key":"1069_CR10","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910\u20136.","journal-title":"N Engl J Med"},{"key":"1069_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/sj.leu.2404441","volume":"21","author":"P Dreger","year":"2007","unstructured":"Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21:12\u20137.","journal-title":"Leukemia"},{"key":"1069_CR12","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1069_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"R Gray","year":"1988","unstructured":"Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141\u201354.","journal-title":"Ann Stat"},{"key":"1069_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature13444","volume":"510","author":"K Ali","year":"2014","unstructured":"Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014;510:407\u201311.","journal-title":"Nature"},{"key":"1069_CR15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","volume":"6","author":"K Okkenhaug","year":"2016","unstructured":"Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 2016;6:1090\u2013105.","journal-title":"Cancer Discov"},{"key":"1069_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/bjh.15181","volume":"184","author":"J Schetelig","year":"2019","unstructured":"Schetelig J, Link CS, Stuhler G, Wagner EM, Hanel M, Kobbe G, et al. Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial. Br J Haematol. 2019;184:833\u20136.","journal-title":"Br J Haematol"},{"key":"1069_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","volume":"54","author":"P Dreger","year":"2019","unstructured":"Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transplant. 2019;54:44\u201352.","journal-title":"Bone Marrow Transplant"},{"key":"1069_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41409-019-0660-8","volume":"55","author":"M Shadman","year":"2020","unstructured":"Shadman M, Maloney DG, Storer B, Sandmaier BM, Chauncey TR, Smedegaard Andersen N, et al. Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. Bone Marrow Transplant. 2020;55:172\u201381.","journal-title":"Bone Marrow Transplant"},{"key":"1069_CR19","doi-asserted-by":"publisher","unstructured":"Sellner L, Schetelig J, Koster L, Choi G, Blaise D, Beelen D, et al. Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. Bone Marrow Transplant. 2020. https:\/\/doi.org\/10.1038\/s41409-020-0946-x.","DOI":"10.1038\/s41409-020-0946-x"},{"key":"1069_CR20","first-page":"3273","volume":"130","author":"P Dreger","year":"2017","unstructured":"Dreger P, Koster L, Passweg JR, Collin M, Scheid C, Charbonnier A, et al. Safety and efficacy of idelalisib treatment of chronic lymphocytic leukemia (CLL) or lymphoma relapsing after allogeneic hematopoietic cell transplantation (alloHCT): a survey by the EBMT chronic malignancies and lymphoma working parties. Blood. 2017;130:3273.","journal-title":"Blood"},{"key":"1069_CR21","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood-2018-01-826008","volume":"132","author":"P Dreger","year":"2018","unstructured":"Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018;132:892\u2013902.","journal-title":"Blood"},{"key":"1069_CR22","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s00432-019-03014-x","volume":"145","author":"NS Andersen","year":"2019","unstructured":"Andersen NS, Bornhauser M, Gramatzki M, Dreger P, Vitek A, Karas M, et al. Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. J Cancer Res Clin Oncol. 2019;145:2823\u201334.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1069_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/bmt.2016.329","volume":"52","author":"J Schetelig","year":"2017","unstructured":"Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, et al. Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2017;52:552\u201360.","journal-title":"Bone Marrow Transplant"}],"updated-by":[{"DOI":"10.1038\/s41409-021-01516-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01069-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T02:03:49Z","timestamp":1636769029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01069-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01069-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41409-021-01516-2","URL":"https:\/\/doi.org\/10.1038\/s41409-021-01516-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JS\u2014consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Molmed; lecturer fees from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Novartis; research support from Genzyme, Sanofi, GSK, Novartis, Abbvie. OH\u2014consultancy honoraria from AB Science; research support from AB Science, Celgene, Alexion, and Inatherys. DG\u2014consultancy honoraria from Roche, Takeda, Iqone; lecturer fees from Abbvie, Celgene, Sanofi-Genzyme; research support from Takeda. NK\u2014lecturer fees from Neovii, Sanofi, Novartis, Kiadis, Celgene, Amgen, Riemser, Chugai, Janssen; research support from Novartis, Celgene, Riemser, Neovii. PD\u2014consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. The remaining authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}